微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2025, Vol. 17 ›› Issue (2): 244-250.doi: 10.3969/j.issn.1674-5671.2025.02.17

• 综述 • 上一篇    下一篇

大分割放疗联合免疫治疗在头颈部鳞状细胞癌中的研究进展

  

  1. 电子科技大学医学院；放射肿瘤学四川省重点实验室，四川省肿瘤临床医学研究中心，四川省肿瘤医院（研究所），四川省癌症防治中心，电子科技大学附属肿瘤医院
  • 出版日期:2025-04-25 发布日期:2025-05-15
  • 通讯作者: 张石川 E-mail：zhangsc65@hotmail.com
  • 基金资助:
    四川省科技计划项目（2022YFSY0055）

Research progress of hypofractionated radiotherapy combined with immunotherapy in head and neck squamous cell carcinoma


  • Online:2025-04-25 Published:2025-05-15

PDF (PC)

5

赞

摘要： 头颈部肿瘤是全球范围内第八大常见癌症，其中90%以上病理分型为头颈鳞状细胞癌（head and neck squamous cell carcinoma, HNSCC）。近年来，随着免疫治疗的快速发展，放疗与免疫治疗的联合应用成为HNSCC治疗的一大研究热点。相较于常规分割放疗，大分割放疗在激发抗肿瘤免疫应答方面表现出更强的效果。另外，大分割放疗联合免疫治疗在复发/转移HNSCC中显示出良好的临床效果和可接受的安全性，其在局部晚期HNSCC的新辅助治疗中也显示了较高的缩瘤和降期效果。本文就大分割放疗联合免疫治疗在HNSCC中的研究进展作一综述，以期为HNSCC的治疗提供新见解。

关键词: 头颈部鳞状细胞癌, 放射治疗, 大分割放疗, 免疫治疗

Abstract: Head and neck cancer ranks as the eighth most common cancer globally, with over 90% histologically classified as head and neck squamous cell carcinoma (HNSCC). In recent years, with the rapid advancement of immunotherapy, the combination of radiotherapy and immunotherapy has emerged as a prominent research focus in the treatment of HNSCC. Compared with conventional fractionation radiotherapy, hypofractionated radiotherapy demonstrates superior efficacy in triggering antitumor immune responses. Additionally, the combination of hypofractionated radiotherapy and immunotherapy has shown favorable clinical outcomes with acceptable safety profiles in recurrent/metastatic HNSCC. In the neoadjuvant therapy for locally advanced HNSCC, it also shows significant tumor reduction and down⁃staging effects. This review summarizes recent advances on hypofractionated radiotherapy combined with immunotherapy for HNSCC, aiming to provide novel insights for the treatment of HNSCC.

Key words:  Head and neck squamous cell carcinoma, Radiotherapy, Hypofractionated radiotherapy, Immunotherapy

中图分类号: 

  •